Management of Hepatitis C Infection
Summary
- High SVR12 rates observed with 8 or 12 weeks of glecaprevir/pibrentasvir with or without ribavirin in phase II and III trials
- SURVEYOR-I/II: SVR12 83% to 100% in genotype 1-6 HCV infection[Kwo 2017a]
- ENDURANCE-1: SVR12 99% to 100% in genotype 1 HCV infection[Zeuzem 2018]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment